S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
S&P 500   4,967.23
DOW   37,986.40
QQQ   414.65
How major US stock indexes fared Friday, 4/19/2024
The Senate passes a reauthorization of a key US surveillance program just after a midnight deadline
Closing prices for crude oil, gold and other commodities
MarketBeat Week in Review – 4/15 - 4/19
Crews turn sights to removing debris from ship's deck in Baltimore bridge collapse cleanup
The drug war devastated Black and other minority communities. Is marijuana legalization helping?
A man escaped Sudan's bloody civil war. His mysterious death in Missisippi has sparked suspicion
NASDAQ:OTIC

Otonomy (OTIC) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
$0.0085
$0.0085
50-Day Range
$0.01
$0.12
52-Week Range
$0.01
$2.54
Volume
N/A
Average Volume
937,525 shs
Market Capitalization
$582,479.50
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
OTIC stock logo

About Otonomy Stock (NASDAQ:OTIC)

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

OTIC Stock News Headlines

Otonomy, Inc.: Otonomy Provides Corporate Update
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
Otonomy Provides Corporate Update
5 Investors Betting Big on Otonomy (OTIC) Stock
Why Is Otonomy (OTIC) Stock Up 97% Today?
Tiny Biotech Stock Wins $75 Billion Patent
A little-known biotech has been quietly working on revolutionary treatments for neurodegenerative diseases. Most people have never heard of them... but those in the know have been taking notice. Jeff Bezos cut them a check for $130 million. Fidelity Biosciences for a further $217 million. They've even had several collaborative partnerships with much larger companies like Biogen, Sanofi, and Takeda.
See More Headlines
Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/20/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:OTIC
Employees
51
Year Founded
N/A

Profitability

Net Income
$-51,180,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$0.97 per share

Miscellaneous

Free Float
67,780,000
Market Cap
$582,479.50
Optionable
Optionable
Beta
1.54
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Paul E. Cayer
    President, CFO, Secretary & Chief Business Officer
  • Anna Stepannenko
    Vice President -Technical operations
  • Fabrice Piu
    Vice President-Research & Preclinical Development
  • David Skarinsky
    Vice President-Clinical
  • Jeffery J. Anderson
    Vice President-Clinical Sciences

OTIC Stock Analysis - Frequently Asked Questions

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) issued its quarterly earnings data on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) EPS for the quarter, hitting analysts' consensus estimates of ($0.19). During the same quarter last year, the firm posted ($0.22) EPS.

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

This page (NASDAQ:OTIC) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners